Prnewswire·2025-12-01 12:00Core Insights - Q32 Bio has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, which allows the company to focus on advancing bempikibart for alopecia areata [1][2][3] - The transaction is expected to provide $12 million in upfront payments and potential total payments of up to $592 million based on future milestones [3][4] - Q32 Bio retains its tissue-targeted complement inhibitor platform, including ADX-096 and other early-stage assets, and is evaluating strategic options for these programs [1][2] Financial Implications - The sale of ADX-097 is projected to extend Q32 Bio's cash runway into the second half of 2027, supporting ongoing clinical trials [2][4] - The upfront payment structure includes $7 million at signing, $3 million at the 6-month anniversary, and $2 million upon achieving a milestone or by the end of 2026 [3] Product Development Focus - Q32 Bio is concentrating on bempikibart (ADX-914), a fully human anti-IL-7R antibody, for the treatment of alopecia areata, with topline data from the SIGNAL-AA Phase 2a trial expected in mid-2026 [2][6] - The company’s tissue-targeted complement platform aims to inhibit complement activation while minimizing systemic effects, differentiating it from current therapies [2][3]